Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 28, 2014. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 620,500 Ordinary Shares of 25 pence each.
- Purchase Date: May 28, 2014.
- Price Range: Highest price paid was 1,619.25 pence per share; lowest price paid was 1,603.00 pence per share.
- Treasury Holdings (Settled): 493,444,212 shares (9.22% of total issued share capital).
- Treasury Holdings (Including Unsettled): 494,710,714 shares (10.19% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,857,169,613 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 620,500 shares. Consequently, the percentage of shares held in Treasury increased to 10.19% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification regarding share repurchases under the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the latest quarterly or annual reports to confirm the 9.22% to 10.19% range.
- Confirm the total issued share capital to validate the denominator used for voting rights calculations (4,857,169,613 shares).
- Check subsequent filings to ensure the unsettled shares mentioned were fully settled and recorded in Treasury.